Macroaxis: Personalized Investing  
Macroaxis Country Selector USA  Change      Macroaxis User Registration Register    Macroaxis User Login Sign In
   
 US Market Closed: Feb 9, 17:38 PM 2012 
  NYSE  8081.25  1.73  Index Moved Down   NASDAQ  2927.23  11.37  Index Moved Up 
 and more..
Search
sponsered by
  
  



Processing
Collecting necessary data for BPTH...
       

Bio-Path financials and fundamentals

       
  Companies   Sectors   Advisers
       
    
       
0.3
  
Bio-Path Quote
Intraday
 
Bio-Path Intraday Quote
One Month
(0.06)  Macroaxis: -16.67 Down   16.67%  
Embed Now
    
Diversification Suggestion
Use Bio-Path to offset short term systematic risk or to hedge overall market volatility. The stock experiences very speculative downward sentiment. The market maybe over-reacting
1 Month Beta vs NYSE ......... -0.78
As returns on NYSE increase, returns on owning Bio-Path are expected to decrease at a much smaller rate. During bear market, Bio-Path is likely to outperform the market
Bio-Path Almost negative beta
    
BPTH Macroaxis: United States OTCBBBio-Path Quote: Bear
Bio-Path Holdings
http://www.biopathholdings.com
801-580-2326
Trade Bio-Path
Run Report
 Run Report 
Correlation
 Correlation 
Peter H. Nielsen executive  Peter H. Nielsen
Co-Founder, Chairman, Chief Office 
Dr. Douglas P. Morris executive Dr. Douglas P. Morris
Co-Founder, VP of Corp. Devel., Sec 
Dr. Ana Maria Tari Ph.D., M.S executive Dr. Ana Maria Tari Ph.D., M.S
Director of Preclinical Operations  

Bio-Path fundamentals

    
Day Low0.30Open0.3199
P/B Ratio6.32Market Cap17.4M
Volume11000SectorHealthcare
Last Close0.36FoundedYes
Last Traded2/9/2012Year HighNot Applicable
Percent ChangePrice Moved Totally Down 16.67% EBITDA-2.3M
Absolute Change0.06 Price Moved DownTimeNot Applicable
Book Value0.057EPS-0.043
Employees2Day High0.3199
Target Price3.00Current EPS-0.043
    

Bio-Path Performance    Embed Financials for Bio-Path Holdings

    
    
 Embed Financials for Bio-Path Holdings

Bio-Path Profile

    
Bio-Path Holdings, Inc., a biotechnology company, through its subsidiary, Bio-Path, Inc., develops liposomal drug delivery systems.
 Macroaxis: United States IXIC   0.39 % Macroaxis: 0.39 Moved Up  
 
 Macroaxis: United States GSPC   0.15 % Macroaxis: 0.15 Moved Up  
 
 Macroaxis: United States NYA   0.02 % Macroaxis: 0.02 Moved Down  
 
 Macroaxis: thisRed BPTH   16.67 % Macroaxis: change 16.67 Moved Down  
 
 Live Sentiment  
 Bulls THOPX 
 NASDAQ Macroaxis: United States 
 Bought over 400 shares of
 43 minutes ago
for 11.47 
 Bulls BCOSX 
 NASDAQ Macroaxis: United States 
 Bought over 400 shares of
 43 minutes ago
for 11.3 
 Bulls TGINX 
 NASDAQ Macroaxis: United States 
 Bought over 300 shares of
 43 minutes ago
for 11.03 
 Bulls MGFIX 
 NASDAQ Macroaxis: United States 
 Bought over 100 shares of
 43 minutes ago
for 26.63 
 Bulls BIDU 
 NASDAQ Macroaxis: United States 
 Bought few shares of
 43 minutes ago
for 132.97 
    

Bio-Path 30-Days Moving Rating

    

Macroaxis Total Score 

    
5
Embed Financials
Current 30 Days Moving Rating
    
    

Estimated Market Risk

 17.15
  actual daily
 
 13 %
of total potential
 
Market Risk score

Expected Return

 1.25
  actual daily
 
 100 %
of total potential
 
Expected Return score

Risk-Adjusted Return

 0.16
  actual daily
 
 10 %
of total potential
 
Risk-Adjusted Return score
Based on monthly moving average   [ change ] 
Increase Risk-Adjusted return of BPTH.OB by adding it to a well-diversified portfolio
Diversify
    

 Bio-Path Last Intraday

    
 
(0.06)Macroaxis: -0.06 Up16.67%
 
0.36,0.36,0.30,0.30,0.3199,0.30,0.30
 
0.360.3
    

Latest headlines for Bio-Path


Few days ago at www.businesswire.com      Got to news item   

First Cohort Successfully Completed in Bio-Path Holdings' Phase I Clinical Trial of Lead Product Candidate...

Business Wire - Aug 11, 2011 HOUSTON--(BUSINESS WIRE)--Bio-Path Holdings, Inc., (OTCBB:BPTH) (?Bio-Path?), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that ... Possible Anti-Leukemia Activity in Liposomal Grb-2 Trial - Drug Discovery & Development
Few days ago at www.reuters.com      Got to news item   

Bio-Path Holdings Signs Equity Financing Deal | Reuters

Equity Purchase Agreement with Institutional Investor Lincoln Park Capital toProvide up to $7 Million in New CapitalHOUSTON--(Business Wire)--Bio-Path Holdings, ...
Few days ago at www.marketwatch.com      Got to news item   

Bio-Path Holdings Announces the Relocation of Corporate Headquarters to Houston, Texas

MarketWatch - Jul 19, 2011 HOUSTON, Jul 19, 2011 (BUSINESS WIRE) -- Bio-Path Holdings, Inc. /quotes/zigman/502559 BPTH -7.81% ("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid ...
Few days ago at www.businesswire.com      Got to news item   

Bio-Path Holdings to Present at the OneMedForum NY Conference

HOUSTON--(BUSINESS WIRE)--Bio-Path Holdings, Inc. (OTCBB: BPTH) (?Bio-Path?), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that ...
Few days ago at www.businesswire.com      Got to news item   

Bio-Path Holdings to Present at the OneMedForum NY Conference

HOUSTON--(BUSINESS WIRE)--Bio-Path Holdings, Inc. (OTCBB: BPTH) (?Bio-Path?), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that ...


 

 
Analytics
Investor Landscape
Efficient Frontier
Market Correlation
Risk and Return Analysis
Financial Content New financial content
Portfolio Projections
Retirement Optimizer
RSS and Mobile Access
Market
FAQs
Stock Screener
Fund Screener
ETF Screener
Company Directory
Advisor Directory
Technology
Wealth Management
About Us
About Macroaxis
Contact Us
Terms Of Use
Privacy Policy
Site Map
Product Tour
Investment Services
More ROI More Return on Investment
© 2011 Macroaxis Inc. All rights reserved